A detailed history of Royal Bank Of Canada transactions in Greenwich Life Sciences, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 1,070 shares of GLSI stock, worth $13,064. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,070
Previous 561 90.73%
Holding current value
$13,064
Previous $9,000 66.67%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$12.99 - $17.58 $6,611 - $8,948
509 Added 90.73%
1,070 $15,000
Q2 2024

Aug 14, 2024

BUY
$12.07 - $19.04 $6,602 - $10,414
547 Added 3907.14%
561 $9,000
Q1 2024

Nov 05, 2024

SELL
$8.31 - $20.32 $4,545 - $11,115
-547 Reduced 97.5%
14 $0
Q1 2024

May 15, 2024

SELL
$8.31 - $20.32 $83 - $203
-10 Reduced 41.67%
14 $0
Q4 2023

Feb 14, 2024

BUY
$7.77 - $12.3 $116 - $184
15 Added 166.67%
24 $0
Q3 2023

Nov 14, 2023

SELL
$8.41 - $10.66 $815 - $1,034
-97 Reduced 91.51%
9 $0
Q2 2023

Aug 14, 2023

SELL
$9.58 - $13.2 $28 - $39
-3 Reduced 2.75%
106 $1,000
Q1 2023

May 15, 2023

SELL
$12.12 - $20.8 $7,162 - $12,292
-591 Reduced 84.43%
109 $1,000
Q4 2022

Feb 14, 2023

SELL
$9.04 - $16.88 $9 - $16
-1 Reduced 0.14%
700 $10,000
Q3 2022

Nov 14, 2022

SELL
$7.81 - $12.02 $5,459 - $8,401
-699 Reduced 49.93%
701 $6,000
Q2 2022

Aug 15, 2022

SELL
$7.14 - $20.36 $1,799 - $5,130
-252 Reduced 15.25%
1,400 $12,000
Q1 2022

May 16, 2022

SELL
$16.3 - $24.65 $9,193 - $13,902
-564 Reduced 25.45%
1,652 $32,000
Q4 2021

Feb 14, 2022

SELL
$21.76 - $39.43 $33,836 - $61,313
-1,555 Reduced 41.24%
2,216 $54,000
Q3 2021

Nov 15, 2021

BUY
$38.65 - $46.11 $26,861 - $32,046
695 Added 22.59%
3,771 $147,000
Q2 2021

Aug 16, 2021

BUY
$31.24 - $53.6 $96,094 - $164,873
3,076 New
3,076 $138,000

Others Institutions Holding GLSI

About Greenwich LifeSciences, Inc.


  • Ticker GLSI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,848,200
  • Market Cap $157M
  • Description
  • Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who ha...
More about GLSI
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.